An Observational, real-world study of Ticagelor versus Clopidogrel in patients with Acute Coronary Syndrome from the SCAAR registry

Trial Profile

An Observational, real-world study of Ticagelor versus Clopidogrel in patients with Acute Coronary Syndrome from the SCAAR registry

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Dec 2016

At a glance

  • Drugs Clopidogrel (Primary) ; Ticagrelor (Primary)
  • Indications Acute coronary syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Dec 2016 New trial record
    • 01 Nov 2016 Primary endpoint (Death or Stent thrombosis at 30 days) has not been met, according to the results in the Journal of the American College of Cardiology
    • 01 Nov 2016 Results published in the Journal of the American College of Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top